Immix Biopharma Inc

Company Profile

Immix Biopharma Inc had its IPO on 2021-12-16 under the ticker symbol IMMX.

The company operates in the Healthcare sector and Biotechnology industry. Immix Biopharma Inc has a staff strength of 9 employees.

Stock update

Shares of Immix Biopharma Inc opened at $2.78 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.65 - $2.97, and closed at $2.78.

This is a -2.11% slip from the previous day's closing price.

A total volume of 257,355 shares were traded at the close of the day’s session.

In the last one week, shares of Immix Biopharma Inc have increased by +21.4%.

Immix Biopharma Inc's Key Ratios

Immix Biopharma Inc has a market cap of $37.30 million, indicating a price to book ratio of 1.1558 and a price to sales ratio of 0.

In the last 12-months Immix Biopharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-11567278. The EBITDA ratio measures Immix Biopharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Immix Biopharma Inc’s operating margin was 0% while its return on assets stood at -41.73% with a return of equity of -73.09%.

In Q2, Immix Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Immix Biopharma Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immix Biopharma Inc’s profitability.

Immix Biopharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.0128. Its price to sales ratio in the trailing 12-months stood at 0.

Immix Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$15.57 million

Total Liabilities

$2.40 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Immix Biopharma Inc ended 2024 with $15.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.57 million while shareholder equity stood at $13.23 million.

Immix Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $2.40 million in other current liabilities, 1634.00 in common stock, $-44041127.00 in retained earnings and $0 in goodwill. Its cash balance stood at $12.65 million and cash and short-term investments were $12.65 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Immix Biopharma Inc’s total current assets stands at $15.51 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $296996.00 compared to accounts payable of $2.40 million and inventory worth $0.

In 2024, Immix Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Immix Biopharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.78

52-Week High

$3.29

52-Week Low

$0.68

Analyst Target Price

$11

Immix Biopharma Inc stock is currently trading at $2.78 per share. It touched a 52-week high of $3.29 and a 52-week low of $3.29. Analysts tracking the stock have a 12-month average target price of $11.

Its 50-day moving average was $2.14 and 200-day moving average was $2.08 The short ratio stood at 1.01 indicating a short percent outstanding of 0%.

Around 5347.9% of the company’s stock are held by insiders while 226.9% are held by institutions.